Dianthus Therapeutics (DNTH) PT Raised to $130 at H.C. Wainwright
March 10, 2026 7:21 AM
H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Dianthus Therapeutics (NASDAQ: DNTH) to $130.00 (from $47.00) while maintaining a Buy rating.
